140.22
price down icon2.31%   -3.31
after-market アフターアワーズ: 140.22
loading
前日終値:
$143.53
開ける:
$144.25
24時間の取引高:
958.27K
Relative Volume:
1.48
時価総額:
$8.52B
収益:
$3.99B
当期純損益:
$463.16M
株価収益率:
19.75
EPS:
7.1
ネットキャッシュフロー:
$1.10B
1週間 パフォーマンス:
+2.58%
1か月 パフォーマンス:
+14.96%
6か月 パフォーマンス:
+28.27%
1年 パフォーマンス:
+17.98%
1日の値動き範囲:
Value
$139.60
$145.40
1週間の範囲:
Value
$134.57
$148.06
52週間の値動き範囲:
Value
$99.06
$148.06

Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile

Name
名前
Jazz Pharmaceuticals Plc
Name
セクター
Healthcare (1170)
Name
電話
353-1-634-7800
Name
住所
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Name
職員
2,800
Name
Twitter
@jazzpharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
JAZZ's Discussions on Twitter

JAZZ を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
JAZZ
Jazz Pharmaceuticals Plc
140.22 8.52B 3.99B 463.16M 1.10B 7.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.31 124.11B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
684.87 74.87B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
622.61 37.83B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
243.53 31.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
111.56 26.75B 3.30B -501.07M 1.03B -2.1146

Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-26 ダウングレード Cantor Fitzgerald Overweight → Neutral
2025-02-13 アップグレード Wells Fargo Equal Weight → Overweight
2024-12-12 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-06-05 開始されました Goldman Buy
2024-01-03 開始されました Robert W. Baird Outperform
2023-11-27 ダウングレード UBS Buy → Neutral
2023-09-29 開始されました Raymond James Mkt Perform
2023-06-12 再開されました Wells Fargo Equal Weight
2022-12-09 アップグレード Goldman Neutral → Buy
2022-06-14 開始されました UBS Buy
2022-04-06 ダウングレード Goldman Buy → Neutral
2021-11-19 再開されました Goldman Buy
2021-10-07 再開されました Jefferies Buy
2021-10-05 開始されました Citigroup Buy
2021-09-23 開始されました Needham Buy
2021-05-19 再開されました JP Morgan Overweight
2021-04-07 再開されました RBC Capital Mkts Outperform
2021-02-05 繰り返されました H.C. Wainwright Buy
2021-02-03 アップグレード Piper Sandler Neutral → Overweight
2021-01-29 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-12-16 開始されました UBS Buy
2020-11-03 繰り返されました H.C. Wainwright Buy
2020-10-09 繰り返されました H.C. Wainwright Buy
2020-09-14 ダウングレード Goldman Neutral → Sell
2020-09-14 再開されました JP Morgan Overweight
2020-08-06 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-07-28 アップグレード Wolfe Research Peer Perform → Outperform
2020-07-23 アップグレード H.C. Wainwright Neutral → Buy
2020-04-06 開始されました Jefferies Buy
2020-03-12 アップグレード Bernstein Mkt Perform → Outperform
2020-01-08 開始されました Goldman Neutral
2019-08-21 ダウングレード Piper Jaffray Overweight → Neutral
2019-06-11 開始されました Barclays Overweight
2019-03-20 開始されました SunTrust Buy
2018-12-14 開始されました Wolfe Research Peer Perform
2018-11-08 繰り返されました B. Riley FBR Buy
2018-08-08 繰り返されました Stifel Buy
2018-07-11 ダウングレード Morgan Stanley Overweight → Equal-Weight
2018-03-23 繰り返されました H.C. Wainwright Neutral
2018-03-19 アップグレード Morgan Stanley Equal-Weight → Overweight
すべてを表示

Jazz Pharmaceuticals Plc (JAZZ) 最新ニュース

pulisher
07:27 AM

Jazz Pharmaceuticals EVP Neena Patil sells shares worth $550,506 - Investing.com

07:27 AM
pulisher
06:52 AM

Jazz Pharmaceuticals plc (JAZZ): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey

06:52 AM
pulisher
12:20 PM

Earnings Estimates Moving Higher for Jazz (JAZZ): Time to Buy? - Nasdaq

12:20 PM
pulisher
Mar 01, 2025

Truist Financial Corp Has $3.52 Million Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) Releases FY 2025 Earnings Guidance - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Needham & Company LLC Raises Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $210.00 - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Jazz downgraded to neutral by Cantor over business strategy - MSN

Feb 28, 2025
pulisher
Feb 28, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues Quarterly Earnings Results - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) Sets New 52-Week HighShould You Buy? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

JPMorgan Chase & Co. Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Principal Financial Group Inc. Decreases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance Australia

Feb 28, 2025
pulisher
Feb 28, 2025

International Markets and Jazz (JAZZ): A Deep Dive for Investors - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Jazz Pharmaceuticals plc Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance

Feb 28, 2025
pulisher
Feb 28, 2025

Jazz Pharmaceuticals Plc to Host Earnings Call - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

Decoding Jazz Pharmaceuticals PLC (JAZZ): A Strategic SWOT Insig - GuruFocus.com

Feb 28, 2025
pulisher
Feb 27, 2025

Investor Network: Jazz Pharmaceuticals Plc to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

New York State Common Retirement Fund Has $6.68 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) Sees Large Volume Increase on Analyst Upgrade - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Cantor Fitzgerald Downgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to Neutral - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns Overweight Rating from Piper Sandler - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Royal Bank of Canada Cuts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $178.00 - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Jazz Earnings: Strong Uptake of Xywav and Epidiolex Drive Sales; Shares Undervalued - Morningstar

Feb 27, 2025
pulisher
Feb 27, 2025

Kovack Advisors Inc. Decreases Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Feb 27, 2025
pulisher
Feb 26, 2025

Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab (JAZZ) - Seeking Alpha

Feb 26, 2025
pulisher
Feb 26, 2025

Strong Uptake of Xywav and Epidiolex Drive Growth for Jazz Pharmaceuticals - Morningstar

Feb 26, 2025
pulisher
Feb 26, 2025

RBC Capital cuts Jazz Pharmaceuticals stock target to $178 By Investing.com - Investing.com UK

Feb 26, 2025
pulisher
Feb 26, 2025

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations - MSN

Feb 26, 2025
pulisher
Feb 26, 2025

Needham lifts Jazz Pharmaceuticals stock target to $210 By Investing.com - Investing.com UK

Feb 26, 2025
pulisher
Feb 26, 2025

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 26, 2025
pulisher
Feb 26, 2025

Jazz Pharmaceuticals plc SEC 10-K Report - TradingView

Feb 26, 2025
pulisher
Feb 26, 2025

RBC Trims Price Target on Jazz Pharmaceuticals to $178 From $179, Keeps Outperform Rating - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Despite the downward trend in earnings at Jazz Pharmaceuticals (NASDAQ:JAZZ) the stock advances 3.2%, bringing five-year gains to 21% - Yahoo Finance

Feb 26, 2025
pulisher
Feb 26, 2025

Jazz: Q4 Earnings Snapshot - The Wilton Bulletin

Feb 26, 2025
pulisher
Feb 26, 2025

Jazz Pharmaceuticals PLC (JAZZ) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance

Feb 26, 2025
pulisher
Feb 26, 2025

Allspring Global Investments Holdings LLC Sells 4,011 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Feb 26, 2025
pulisher
Feb 25, 2025

Jazz Pharmaceuticals PLC reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 25, 2025
pulisher
Feb 25, 2025

Jazz Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

Earnings call transcript: Jazz Pharmaceuticals Q4 2024 beats EPS forecasts - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics - Yahoo Finance

Feb 25, 2025
pulisher
Feb 25, 2025

Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance

Feb 25, 2025
pulisher
Feb 25, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales - Yahoo Finance

Feb 25, 2025
pulisher
Feb 25, 2025

Jazz Pharmaceuticals Q4 Non-GAAP Earnings, Revenue Rise; 2025 Guidance Issued - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

Jazz: Q4 Earnings Snapshot -February 25, 2025 at 04:44 pm EST - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

Jazz Pharmaceuticals reports strong Q4, but shares slip on muted 2025 outlook - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Jazz Pharmaceuticals 8-K Filing Analysis - TradingView

Feb 25, 2025
pulisher
Feb 25, 2025

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance - PR Newswire

Feb 25, 2025
pulisher
Feb 25, 2025

Jazz Pharmaceuticals stock hits 52-week high of $139 By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 24, 2025

Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect - Yahoo Finance

Feb 24, 2025
pulisher
Feb 21, 2025

First Week of April 17th Options Trading For Jazz Pharmaceuticals - Nasdaq

Feb 21, 2025

Jazz Pharmaceuticals Plc (JAZZ) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$310.03
price down icon 3.13%
$19.13
price down icon 7.54%
$22.96
price up icon 1.23%
$33.86
price up icon 0.65%
biotechnology ONC
$245.53
price down icon 9.67%
$111.56
price down icon 1.20%
大文字化:     |  ボリューム (24 時間):